Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549114 · ClinicalTrials.gov registry record · Phase 2
Leniolisib for Immune Dysregulation in PIDs
A Phase 2 study of Primary Immunodeficiency Disorders (PIDs), sponsored by Pharming Technologies B.V..
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06549114 is a Phase 2 study of Primary Immunodeficiency Disorders (PIDs) that is active but no longer recruiting, run by Pharming Technologies B.V.. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06549114, a Phase 2 study of Primary Immunodeficiency Disorders (PIDs), is active but no longer recruiting, sponsored by Pharming Technologies B.V..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.
Conditions Studied
Interventions
- DRUG Leniolisib
Study Locations (1)
Maryland
- National Institute of Health - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06549114
The ClinicalTrials.gov registry entry for NCT06549114 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharming Technologies B.V., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immunodeficiency Disorders (PIDs) appearing as the primary indexed condition, and to 1 intervention - of which Leniolisib is the first listed.
NCT06549114 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06549114 about?
NCT06549114 is a clinical study titled "Leniolisib for Immune Dysregulation in PIDs". This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three differen...
What is the current status of trial NCT06549114?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-10-21. Estimated completion is 2026-11.
What conditions does trial NCT06549114 study?
This clinical trial studies the following conditions: Primary Immunodeficiency Disorders (PIDs).
What interventions are being tested in trial NCT06549114?
The interventions under investigation include: Leniolisib (DRUG).
Who is sponsoring clinical trial NCT06549114?
This trial is sponsored by Pharming Technologies B.V., which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06549114 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.